Delphia (USA)’s Century Therapeutics IPSC Stock Holding History

Delphia (USA)’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,548	Closed	-$89K	–	353
2022 Q2	$89K	Buy	+10,548	New	+$103K	0.06%	347

Other funds holding IPSC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Delphia (USA)'s IPSC Position: Q3 2022 in Review

Delphia (USA) sold out of Century Therapeutics (IPSC) in Q3 2022, closing a stake of 10,548 shares — an estimated $89K sold.

Delphia (USA) first reported a position in IPSC in Q2 2022 and held it in 1 quarter. The position peaked at $89K in Q2 2022. 54 funds tracked by Wall St. Rank hold IPSC as of Q3 2022.

Delphia (USA) reported no remaining Century Therapeutics position as of Q3 2022 after selling out during the quarter.
Delphia (USA) sold 10,548 Century Therapeutics shares in Q3 2022, an estimated $89K.
Delphia (USA) first reported a position in Century Therapeutics in Q2 2022 and held it in 1 quarter.
Delphia (USA)'s Century Therapeutics position peaked at $89K in Q2 2022.
54 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.